Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). …

Peptide Receptor Radionuclide Therapy (PRRT) with radiolabelled somatostatin analogues
is a promising treatment option for patients with inoperable or metastasised neuroendocrine …

Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a
promising option for the treatment of somatostatin-receptor-positive endocrine tumors. …

Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs)
are slowgrowing, median overall survival (OS) in patients with liver metastases is 2 to 4 …

Quality of life (QOL) is an important outcome in cancer therapy. In this study, we investigated
the QOL and symptoms after [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu-octreotate) therapy …

Therapy using the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate (
177 Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic …

Somatostatin receptor imaging with [ 111 In-DTPA 0 )octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors. Treatment with …

In patients with neuroendocrine tumours (NETs), a combination of morphological imaging
and nuclear medicine techniques is mandatory for primary tumour visualization, staging and …

Purpose Foregut carcinoid tumours have a different embryological origin than other
gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n = …

Regular therapy with the radiolabeled somatostatin analog 177 Lu-octreotate (22.2–29.6
GBq) in patients with gastroenteropancreatic or bronchial neuroendocrine tumors results in …